Anti-TIGIT Antibodies and Usage Method

The EPO published patent application EP4089115A1 for Shanghai Henlius Biotech covering anti-TIGIT antibodies and their usage methods for therapeutic applications, particularly cancer treatment. The application was published on April 8, 2026, with inventors YANG Ming, XU Wenfeng, JIANG Wei-Dong, and XUE Jie. The patent is classified under multiple IPC codes including C07K 16/28 (antibodies) and A61P 35/00 (antitumor agents).

For biotech and pharmaceutical companies, this patent publication establishes intellectual property protection for anti-TIGIT antibody technology in European markets. Companies developing similar免疫 checkpoint inhibitors targeting TIGIT should review Freedom to Operate implications in designated European states. The patent's broad classification coverage (antibodies, nucleic acids, compositions) suggests extensive protection for the antibody scaffold and therapeutic applications.